Company / Operating Cash Flow
Avalo Therapeutics, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$51.5M
FY2025
5-year range
-$70.9M / -$26.8M
FY2021-FY2025
Trend
-4.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 3 consecutive years, from -$27M in FY2022 to -$51M in FY2025.
Based on SEC 10-K filings.
-$51M in FY2025.
Declined from -$31M to -$51M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Avalo Therapeutics, Inc.'s operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 4.9% year-over-year.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$51.5M | -4.9% |
| FY2024 | -$49.1M | -59.9% |
| FY2023 | -$30.7M | -14.7% |
| FY2022 | -$26.8M | +62.3% |
| FY2021 | -$70.9M | -74.9% |
| FY2020 | -$40.5M | -111.9% |
| FY2019 | -$19.1M | -511.7% |
| FY2018 | -$3.1M | -124.9% |
| FY2017 | $12.6M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026